Stüve O, Korth C, Gabatto P, Cameron EM, Hu W, Eagar TN, Monson NL, Frohman EM, Racke MK, Zabetian CP, Oksenberg JR. Genetic Polymorphism at Codon 129 of the Prion Protein Gene Is Not Associated With Multiple Sclerosis. Arch Neurol. 2009;66(2):280-281. doi:10.1001/archneur.66.2.280
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009
The endogenous cellular prion protein (PrPC) is an α-helical glycophosphatidylinositol-anchored sialoglycoprotein highly expressed in neurons, lymphoid cells, and myeloid cells. In humans, the PrP gene (Prnp) is located on chromosome 20p12. Single-nucleotide polymorphisms (SNPs) in Prnp have been shown to determine the susceptibility to inherited, sporadic, and infectious forms of prion diseases.1 Interestingly, it was also recently shown that the same Prnp129 SNP has a significant effect on the clinical course of numerous nonprion neurodegenerative disorders of the central nervous system (CNS), including early-onset Alzheimer disease,2- 4 Down syndrome,5 and Wilson disease.6 In these studies, methionine/valine (M/V) heterozygosity was associated with less severe clinical disease. Finally, the Prnp129 SNP was also shown to negatively affect long-term memory in adult and senescent healthy individuals.7- 9 The exact mechanisms by which genetic polymorphisms of Prnp alter CNS function and disease phenotypes are largely unknown.
In this study, we investigated the effect of the Prnp129 M/V SNP on disease susceptibility to multiple sclerosis (MS), a human inflammatory neurodegenerative disease of the CNS. To determine whether the Prnp129 M/V SNP plays a role in MS susceptibility, we genotyped 973 families with nuclear MS (n = 2998 individuals). Appropriate institutional review boards approved the studies and informed consent was obtained from all participants. The ratio of women to men for affected individuals was 2.9:1, and 91.7% presented with relapsing-remitting (67.6%) or secondary progressive (24.1%) MS at the time of study entry. Genotypes were generated by a TaqMan allelic discrimination assay on an ABI7900HT genotyping platform using the Assay-by-Design service from Applied Biosystems (Foster City, California). All family genotypes were examined for mendelian inconsistencies using PedCheck (University of Pittsburgh, Pennsylvania),10 and any discrepancies were addressed. No deviations from Hardy-Weinberg equilibrium were observed for genotypes in the patient, parent, or combined group (data not shown).
Family-based association analysis was performed using the reconstructed-combined transmission disequilibrium test11 as implemented in SAS Genetics (v.9.1.3; SAS Institute, Cary, North Carolina). There was no evidence of transmission distortion in this data set (P = .5). Families were stratified by sex and by the presence of HLA-DRB1*1501 in the affected individuals to identify potential genetic interactions. No difference in allelic transmission was observed in either subgroup. The cases from the 973 families with nuclear MS were combined with 490 additional MS cases (total ratio of women to men, 2.7:1) ascertained using identical inclusion criteria and compared with 1131 controls (ratio of women to men, 1.9:1). There was no statistically significant difference in the frequency of Prnp129 genotypes between patients and controls. Allele frequency distributions were similar in patients with mild (EDSS < 3, 15 years after onset) or severe (EDSS > 6 within 10 years after onset) MS (data not shown)12 or when using the Multiple Sclerosis Severity Score13 as a dependent variable (data not shown). Similarly, no effect of Prpn129 on age of onset was detected.
Using the family-based association analysis, we can conclude that an SNP in Prnp129 plays no major role in MS susceptibility. The role of other unlinked polymorphisms or the potential role of Prnp129 in the progression of neuroradiologic or cognitive endpoints of MS cannot be excluded.
Correspondence: Dr Stüve, Neurology Section, Veterans Affairs North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216 (firstname.lastname@example.org).
Author Contributions:Study concept and design: Stüve, Korth, Hu, Frohman, and Oksenberg. Acquisition of data: Stüve, Gabatto, Cameron, Monson, Frohman, Zabetian, and Oksenberg. Analysis and interpretation of data: Stüve, Korth, Eagar, Monson, Frohman, Racke, and Oksenberg. Drafting of the manuscript: Stüve, Korth, Hu, Eagar, Monson, Frohman, and Oksenberg. Critical revision of the manuscript for important intellectual content: Stüve, Korth, Gabatto, Cameron, Frohman, Racke, Zabetian, and Oksenberg. Statistical analysis: Stüve and Oksenberg. Obtained funding: Monson, Racke, Zabetian, and Oksenberg. Administrative, technical, and material support: Stüve, Korth, Gabatto, Hu, Eagar, Frohman, and Zabetian. Study supervision: Stüve, Korth, Monson, Zabetian, and Oksenberg.
Financial Disclosure: None reported.
Additional Contributions: The authors wish to thank the individuals who participated in this study.